Are Vitamin D Levels Key to Canagliflozin's Fracture Risk? Are Vitamin D Levels Key to Canagliflozin's Fracture Risk?
Study findings suggest that patients be screened for vitamin D deficiency before starting SGLT2 inhibitor therapy, or they should simply be prescribed vitamin D supplements.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 22, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Canagliflozin Reduces Cardiorenal Biomarkers in T2D
WEDNESDAY, Aug. 23, 2023 -- For people with type 2 diabetes and albuminuria, canagliflozin reduces the longitudinal trajectory of increase in cardiorenal biomarkers, according to a study published online Aug. 22 in Circulation.
James L. Januzzi,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 23, 2023 Category: Pharmaceuticals Source Type: news
Billionaire Mark Cuban Is Pulling Off His Biggest Bet
The billionaire's online pharmacy will offer one of the most expensive treatments for type 2 diabetes at half the price. Mark Cuban is on a mission to disrupt the drug industry. The tech billionaire co-founded online pharmacy CostPlus Drug Company, the only company that bears his name, in January…#markcuban #costplusdrugcompany #cuban #janssen #johnsonjohnson #invokana #twitter #drugscom #canagliflozin #costdrugs (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2023 Category: Consumer Health News Source Type: news
Mark Cuban Announces Big News for People with Diabetes
The billionaire's online pharmacy will offer one of the most expensive treatments for type 2 diabetes at half the price. Mark Cuban is on a mission to disrupt the drug industry. The tech billionaire co-founded online pharmacy CostPlus Drug Company, the only company that bears his name, in January…#markcuban #costplusdrugcompany #cuban #janssen #johnsonjohnson #invokana #twitter #drugscom #canagliflozin #thestreet (Source: Reuters: Health)
Source: Reuters: Health - April 4, 2023 Category: Consumer Health News Source Type: news
Canagliflozin Improves HF Symptoms in Fully Remote Trial Canagliflozin Improves HF Symptoms in Fully Remote Trial
The benefit of the SGLT2 inhibitor was consistent, regardless of ejection fraction and presence or absence of type 2 diabetes, in the decentralized CHIEF-HF trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 17, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Johnson & Johnson Reports Q3 2021 Results
New Brunswick, N.J. (October 19, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2021. “Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health,” said Alex Gorsky, Chairman and Chief Executive Officer. “In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders, ...
Source: Johnson and Johnson - October 19, 2021 Category: Pharmaceuticals Tags: Financial Source Type: news
La FDA revisa la etiqueta del medicamento para diabetes canagliflozina (Invokana, Invokamet) para incluir actualizaciones sobre el riesgo de fracturas óseas y nueva información sobre la disminución de la densidad mineral ósea
[10-09-2015] La Administraci ón de Alimentos y Medicamentos (FDA, por sus siglas en inglés) de los Estados Unidos ha reforzado la advertencia del medicamento para la diabetes tipo 2 canagliflozina (Invokana, Invokamet) que se relaciona con el aumento en el riesgo de fracturas óseas, y agregó nueva información sobre la dism inución de la densidad mineral ósea. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 2, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Canagliflozin in T2DM-related nephropathy improves QALYs, reduces cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2020 Category: Drugs & Pharmacology Source Type: news
Canagliflozin Beneficial Even for Advanced Kidney Disease
MONDAY, Nov. 30, 2020 -- Treatment with the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduces the rate of kidney disease progression among participants with an estimated glomerular filtration rate (eGRF)<30 mL/min/1.73 m2,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 30, 2020 Category: Pharmaceuticals Source Type: news
' Good News' From the FDA on Dulaglutide, Canagliflozin'Good News' From the FDA on Dulaglutide, Canagliflozin
Two label changes from the FDA mean good news for patients with diabetes, says Dr Anne Peters.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 8, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news
FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 8, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
SGLT2 inhibitors can slow progression of chronic kidney disease
(ERA-EDTA) The CREDENCE trial [3] provided evidence that the SGLT2 inhibitor Canagliflozin slows the progression of CKD in individuals with type 2 diabetes (T2D) and CKD with albuminuria. The Phase III DAPA-CKD trial [1] has now shown that the SGLT2 inhibitor Dapagliflozin can significantly slow CKD progression in all CKD patients, not only in those with diabetes. This breakthrough in kidney disease treatment goes back to an incidental study finding of Professor Christoph Wanner, President of the ERA-EDTA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 31, 2020 Category: International Medicine & Public Health Source Type: news
FDA Pulls Amputation Boxed Warning Off Canagliflozin Label FDA Pulls Amputation Boxed Warning Off Canagliflozin Label
New safety information suggests the risk of amputation, while still increased with canagliflozin, is lower than previously described, particularly when appropriately monitored, the FDA said.News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 26, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news
Invokana, Invokamet, Invokamet XR (canagliflozin): MedWatch Safety Alert - Boxed Warning about Risk of Leg and Foot Amputations Removed
Based on FDA's review of new data from three clinical trials, the Boxed Warning about amputation risk from the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) prescribing information was removed. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 26, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
